PADI4 and systemic lupus erythematosus: Thus, the demonstrated benefits of PAD inhibition in experimental models of lupus, attributed to a decreased burden of NETosis (18, 101), may indeed be mediated by alternative mechanisms, such as the transcriptional regulation of anti-inflammatory pathways by these inhibitors.